Additionally, somatostatin can inhibit gastrointestinal activities, reducing the secretion of pancreatic enzymes and gastric acid, thereby indirectly lowering the demand for glucagon GLP-1 , ,
At LifeRx.md , weve seen firsthand how confusing it can be to not see the results you expected
One of the most overlooked causes of increased sun sensitivity in Wegovy patients isn't the GLP-1 agonist itself, but other medications they may be taking concurrently
The subsequent phase 3 trial of tirzepatide demonstrated more effective reductions in the glycated hemoglobin levels and body weight, along with greater overall improvements in the lipid profile compared to semaglutide in patients with T2DM, elevating incretin therapeutic agents to a new level (112)
doi: 10.1111/aji.12420
Donna Ryan, an obesity medicine specialist at Pennington Biomedical Research Center